The contract is for the advanced preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome
Acute radiation syndrome
(ARS) is a group of health effects that occur within several days to months after exposure to high doses of ionizing radiation from a nuclear event such as a nuclear power plant accident.
According to the company, its lead compound, AEOL 10150, is being developed for the treatment of pulmonary syndrome of Acute Radiation Syndrome
(Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a contract with BARDA.
has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015, being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for acute radiation syndrome
, the company said.
M2 PHARMA-June 29, 2015-Aeolus Pharmaceuticals reports Barda's exercises of USD3m in additional contract funding for development of AEOL 10150 for Acute Radiation Syndrome
It was reported yesterday that the company has received the designation for OrbeShield for the reduction of mortality associated with gastrointestinal acute radiation syndrome
Nasdaq:MAXY) today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome
(ARS) will not be considered for a contract award.
Most of the options are for the period of performance beginning 1 April 2012 and ending 31 March 2013 and include funding for murine and NHP Efficacy studies in Lung Acute Radiation Syndrome
(Lung-ARS), GMP manufacturing and project management costs.
WASHINGTON -- The development of five new drugs to treat injuries associated with acute radiation syndrome
will move forward under contracts awarded by the U.
69m year-on-year, reflecting the acceleration of the company's Pulmonary Acute Radiation Syndrome
programme and manufacturing of compound for its planned oncology study in 2011.
7 million by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of Acute Radiation Syndrome
New contracts fund drugs to treat gastrointestinal tract injuries of acute radiation syndrome